Targeting growth factor supply in keratopathy treatment: comparison between maternal peripheral blood and cord blood as sources for the preparation of topical eye drops.

BACKGROUND Epitheliotrophic growth factors (GF) can be supplied topically to patients with severe keratopathy through a variety of blood-derived products. We compared GF content in adult peripheral blood serum (PB-S) and cord blood serum (CB-S) as potential sources of GF. To limit inter-individual variability the assessment was performed in maternal-child pairs at the time of delivery. MATERIAL AND METHODS The amounts of epidermal GF (EGF), insulin-like GF (IGF), transforming GF-beta (TGF-β), vascular endothelial GF (VEGF) in CB units collected from the umbilical vein and PB from mothers (each group n=30) were estimated by enzyme-linked immunosorbent assays. Obstetric characteristics and haematological data were recorded from the archives of the Emilia Romagna Cord Blood Bank. Statistical evaluations were performed by Wilcoxon's test and correlations between variables were determined using Spearman's (ρ) coefficient; p-values <0.05 were considered statistically significant. RESULTS EGF, TGF-β and VEGF levels were significantly higher in CB-S than in PB-S (median 1,254.4 vs 646.0 pg/mL, 51.3 vs 38.4 μg/mL and 686.8 vs 30 pg/mL, respectively; all p<0.0001) whereas IGF content was significantly higher in PB-S than in CB-S (159.9 vs 53.5 pg/mL, respectively; p<0.0001). In CB-S, the CD34(+) cell concentration appeared to be related to EGF, IGF and TGF-β levels whereas white blood cell count appeared to be related to EGF and TGF-β levels. VEGF levels showed no relation to the haematological parameters considered. Platelet counts were not related to GF level in either CB or PB. DISCUSSION The GF content in the two blood sources was different, with CB containing larger amounts. Each GF selectively regulates cellular processes involved in corneal healing, so the use of PB or CB should be targeted to supply specific GF on the basis of the type and severity of the keratopathy.

[1]  H. Ullum,et al.  Ready‐made allogeneic ABO‐specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy , 2014, Acta ophthalmologica.

[2]  M. Rosenblatt,et al.  Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  E. Campos,et al.  Efficacy of Standardized and Quality-Controlled Cord Blood Serum Eye Drop Therapy in the Healing of Severe Corneal Epithelial Damage in Dry Eye , 2013, Cornea.

[4]  P. Martínez-Carpio,et al.  Posology, efficacy, and safety of epidermal growth factor eye drops in 305 patients: logistic regression and group-wise odds of published data. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  Cristhian A. Urzua,et al.  Randomized Double-Blind Clinical Trial of Autologous Serum Versus Artificial Tears in Dry Eye Syndrome , 2012, Current eye research.

[6]  J. Alió,et al.  The role of "eye platelet rich plasma" (E-PRP) for wound healing in ophthalmology. , 2012, Current pharmaceutical biotechnology.

[7]  Won Choi,et al.  Application of Umbilical Cord Serum Eyedrops for Recurrent Corneal Erosions , 2011, Cornea.

[8]  R. Tandon,et al.  Evaluation of umbilical cord serum therapy in acute ocular chemical burns. , 2011, Investigative ophthalmology & visual science.

[9]  S. Rossi,et al.  Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal lesions , 2011, The Journal of pharmacy and pharmacology.

[10]  Chung-Tien Lin,et al.  Comparison of Corneal Epitheliotrophic Capacity Among Different Human Blood–derived Preparations , 2011, Cornea.

[11]  J. Hassell,et al.  The molecular basis of corneal transparency. , 2010, Experimental eye research.

[12]  J. Durán,et al.  Plasma Rich in Growth Factors as a Therapeutic Agent for Persistent Corneal Epithelial Defects , 2010, Cornea.

[13]  T. Nishida,et al.  IGF‐1 released by corneal epithelial cells induces up‐regulation of N‐cadherin in corneal fibroblasts , 2009, Journal of cellular physiology.

[14]  J. Hassell,et al.  The effect of growth factor signaling on keratocytes in vitro and its relationship to the phases of stromal wound repair. , 2009, Investigative ophthalmology & visual science.

[15]  Y. Tsai,et al.  Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect , 2009, Eye.

[16]  K. Yoon,et al.  Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. , 2007, Ophthalmology.

[17]  I. Montero-de-Espinosa,et al.  Aplicación subconjuntival de concentrado de plaquetas plasmáticas en el tratamiento de quemaduras oculares. Resultados preliminares , 2007 .

[18]  K. Yoon,et al.  Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome. , 2007, American journal of ophthalmology.

[19]  K. Yoon,et al.  Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease , 2007, Bone Marrow Transplantation.

[20]  W. Sekundo,et al.  Autologous serum for the treatment of corneal epithelial abrasions in diabetic patients undergoing vitrectomy. , 2006, American journal of ophthalmology.

[21]  T. Wedel,et al.  Corneal epitheliotrophic capacity of three different blood-derived preparations. , 2006, Investigative ophthalmology & visual science.

[22]  K. Yoon,et al.  Application of Umbilical Cord Serum Eyedrops for the Treatment of Dry Eye Syndrome , 2006, Cornea.

[23]  Sandra M. Brown,et al.  The effect of autologous serum eye drops in the treatment of severe dry eye disease: a prospective randomized case-control study. , 2005, American journal of ophthalmology.

[24]  Christine P. Dancey,et al.  Statistics Without Maths for Psychology: Using Spss for Windows , 2005 .

[25]  I. Martineau,et al.  Platelet-rich Plasmas: Growth Factor Content and Roles in Wound Healing , 2005, Journal of dental research.

[26]  T. Wedel,et al.  An optimised protocol for the production of autologous serum eyedrops , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[27]  G. Geerling,et al.  Autologous serum eye drops for ocular surface disorders , 2004, British Journal of Ophthalmology.

[28]  J. Zhao,et al.  [Organ culture for preservation of the cornea: human umbilical cord serum versus fetal bovine serum]. , 2004, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[29]  K. Pesudovs,et al.  Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease , 2004, British Journal of Ophthalmology.

[30]  R. Pandey,et al.  Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects , 2003, The British journal of ophthalmology.

[31]  J. Jester,et al.  Modulation of cultured corneal keratocyte phenotype by growth factors/cytokines control in vitro contractility and extracellular matrix contraction. , 2003, Experimental eye research.

[32]  T. Chikama,et al.  Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1 , 2003, Diabetologia.

[33]  K. Tsubota,et al.  Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease , 2003, Bone Marrow Transplantation.

[34]  H. Taylor,et al.  Controlled Study of the Use of Autologous Serum in Dry Eye Patients , 2001, Cornea.

[35]  J. Daniels,et al.  Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies , 2001, The British journal of ophthalmology.

[36]  A. Ljubimov,et al.  Altered expression of growth factors and cytokines in keratoconus, bullous keratopathy and diabetic human corneas. , 2001, Experimental eye research.

[37]  G. Palumbo,et al.  Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis , 2001, Leukemia.

[38]  C. Sotozono,et al.  The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. , 2001, Experimental eye research.

[39]  P. Khaw,et al.  Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. , 2001, Investigative ophthalmology & visual science.

[40]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[41]  C. Sotozono,et al.  Growth factors: importance in wound healing and maintenance of transparency of the cornea , 2000, Progress in Retinal and Eye Research.

[42]  K. Tsubota,et al.  Treatment of persistent corneal epithelial defect by autologous serum application. , 1999, Ophthalmology.

[43]  K. Tsubota,et al.  Treatment of dry eye by autologous serum application in Sjögren’s syndrome , 1998, The British journal of ophthalmology.

[44]  C. Murphy,et al.  Synergistic effects of substance P with insulin‐like growth factor‐1 on epithelial migration of the cornea , 1996, Journal of cellular physiology.

[45]  D. Musch,et al.  Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. Chiron Vision Fibronectin Study Group. , 1995, American journal of ophthalmology.

[46]  S. Tseng,et al.  Growth factors modulate clonal growth and differentiation of cultured rabbit limbal and corneal epithelium. , 1993, Investigative ophthalmology & visual science.

[47]  P. Khaw,et al.  Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis. , 1992, Investigative ophthalmology & visual science.

[48]  J. F. Gordon,et al.  Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. , 1992, American journal of ophthalmology.

[49]  J. Winer,et al.  The vascular endothelial growth factor family of polypeptides , 1991, Journal of cellular biochemistry.

[50]  S. Kinoshita,et al.  The mechanism of accelerated corneal epithelial healing by human epidermal growth factor. , 1990, Investigative ophthalmology & visual science.

[51]  S Kinoshita,et al.  Presence of epidermal growth factor in human tears. , 1989, Investigative ophthalmology & visual science.

[52]  J. Ubels,et al.  Retinol secretion by the lacrimal gland. , 1986, Investigative ophthalmology & visual science.

[53]  J. Belmont,et al.  Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. , 1984, Arthritis and rheumatism.

[54]  S. Cohen,et al.  Epidermal growth factor , 1972, The Journal of investigative dermatology.

[55]  E. Campos,et al.  Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels. , 2014, Blood transfusion = Trasfusione del sangue.

[56]  Meifang Zhu,et al.  Cellular distribution of the IGF-1R in corneal epithelial cells. , 2012, Experimental eye research.

[57]  Rafael Márquez De Aracena Del Cid,et al.  Subconjunctival application of regenerative factor-rich plasma for the treatment of ocular alkali burns , 2009 .

[58]  Gerd Geerling,et al.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[59]  K. Tsubota,et al.  Autologous serum eye drops for dry eye after LASIK. , 2006, Journal of refractive surgery.

[60]  A. Larsson,et al.  Serum and plasma levels of FGF-2 and VEGF in healthy blood donors , 2004, Angiogenesis.

[61]  K. Islam,et al.  Vascular endothelial growth factor induced functional and morphologic signs of endothelial dysfunction in isolated arteries from normal pregnant women. , 2003, American journal of obstetrics and gynecology.

[62]  V. Madrid-Marina,et al.  Factor de crecimiento transformante beta-1 : estructura , función y mecanismos de regulación en cáncer , 2001 .

[63]  A. Adamis,et al.  Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. , 1998, Investigative ophthalmology & visual science.

[64]  M. Ohji,et al.  Transforming growth factor-β stimulates collagen and fibronectin synthesis by human corneal stromal fibroblasts in vitro , 1993 .

[65]  J. Imanishi,et al.  Distribution of epidermal growth factor (EGF) receptors in rabbit corneal epithelial cells, keratocytes and endothelial cells, and the changes induced by transforming growth factor-β1 , 1992 .